Pomalidomide

Drug Profile

Pomalidomide

Alternative Names: Actimid; CC-4047; CDC-394; Imnovid; Pomalidomide-Celgene; Pomalyst

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Celgene Corporation
  • Developer Celgene Corporation; Dana-Farber Cancer Institute; Sarah Cannon Research Institute; University of Texas M. D. Anderson Cancer Center
  • Class Anti-inflammatories; Antineoplastics; Phthalimides; Piperidones; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Cytokine modulators; Interleukin 6 inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple myeloma
  • Phase II Systemic scleroderma
  • Phase I/II Amyloid light-chain amyloidosis
  • Phase I Waldenstrom's macroglobulinaemia
  • No development reported Myelofibrosis; Pancreatic cancer; Sickle cell anaemia; Small cell lung cancer

Most Recent Events

  • 03 Aug 2017 Celgene plans a phase II trial for Brain cancer (Monotherapy, In children, In adults, Recurrent) in France, Italy, Spain, United Kingdom and USA (EudraCT2016-002903-25)
  • 03 Jul 2017 Ohio State University Comprehensive Cancer Center and Celgene suspends phase I trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, for internal data analysis (NCT02569320)
  • 22 Jun 2017 Interim efficacy and adverse events data from a phase-II trial in Multiple myeloma presented at the 22nd Congress of the European Haematology Association (EHA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top